ABALOPARATIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743	NDA	Radius Health, Inc.	70539-001-02	1 CARTRIDGE in 1 BOX, UNIT-DOSE (70539-001-02) / 1.56 mL in 1 CARTRIDGE (70539-001-01)	2017-05-01
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743	NDA	Radius Health, Inc.	70539-001-98	1 CARTRIDGE in 1 BOX, UNIT-DOSE (70539-001-98) / 1.56 mL in 1 CARTRIDGE (70539-001-99)	2017-05-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 23, 2026

Abaloparatide Suppliers: Who Manufactures, Supplies, and Provides IP-Relevant Components Across the Supply Chain

Abaloparatide is supplied commercially through an injectable supply chain tied to the branded product Tymlos (abaloparatide injection, USP). The core supplier set is anchored by: (1) the original brand owner and regulatory holder for Tymlos, (2) the contract manufacturing organizations (drug substance and drug product) used for steriles injectables, and (3) critical raw-material and device-component suppliers used in prefilled pen injection systems.

What follows is the supplier map for abaloparatide supply chain decisions (licensing, sourcing, CMO qualification, litigation posture, and biosimilar or generic feasibility).

Who are the key suppliers for Tymlos (abaloparatide injection) manufacture?

Regulatory holder / brand owner supplier anchor

Radius Health, Inc. was the original developer and brand owner for Tymlos (abaloparatide injection).
Tymlos is marketed in the US under the brand name Tymlos (abaloparatide).

Contract manufacturing supply chain: how to treat supplier questions for sterile injectables

For abaloparatide, suppliers should be scoped into two layers for operability and freedom-to-operate analysis:

Drug substance (API) manufacture and intermediates
Drug product (sterile, prefilled pen) manufacture
- Sterile fill-finish
- Prefill system assembly compatibility
- Device-pen components (if supplied separately from DP CMO)
Critical components
- Pen hardware and dosing mechanism parts
- Container closure system compatibility
- Sterility assurance inputs (filters, tubing, sterilants)
- Preservative and buffer excipients

Supplier identification for this layer depends on the FDA facility listings and label “Manufactured for” statements and is typically not fully discoverable from public generic sources without the exact product label and inspection lists.

Which CDMOs manufacture abaloparatide drug product and prefilled pen injectors?

Sterile fill-finish supplier pattern for prefilled injectables

Abaloparatide is delivered as a prefilled pen. For this product category, drug product manufacturing is usually performed by a sterile fill-finish CDMO that provides:

Aseptic processing and sterile filtration
Filling, capping/closure integration
Prefill pen assembly (or pen-device component integration)
Final packaging and labeling

Supplier decisions require facility-level attribution (not corporate-level) because:

A branded product may use one fill-finish site for commercial supply and separate sites for tech transfer/launch lots.
Pen-device sourcing can shift between vendors without changing DP CMO identity.

What companies supply abaloparatide API and key intermediates?

API supplier: scope for supply and IP risk

Abaloparatide API manufacture includes:

Complex peptide/chemical synthesis or peptide-like intermediate steps (depending on route)
Purification and crystallization or final purification strategy
Control of impurities tightly tied to spec

From an R&D and licensing lens, the key supplier question is not only “who makes API,” but also:

Who owns or controls the process IP for API
Whether the API CMO is also the source of impurity control strategies that are often tied to patents and regulatory submissions

Publicly verifiable supplier identification for abaloparatide API is typically found in FDA drug application chemistry/manufacturing inspections, post-approval amendments, and label/manufacturing disclosures.

How many suppliers are typically in the abaloparatide supply chain?

For a prefilled sterile injectable, a practical supplier topology usually spans:

1–2 drug substance sites (API manufacture)
1 primary drug product sterile fill-finish site for commercial batches
1–2 device/pen component suppliers (depending on vertical integration)
Multiple excipient and critical component suppliers (buffers, tonicity agents, surfactants, filters, and closure-related materials)

This supplier topology is standard for injectable peptide analog supply chains and is used to structure CMO qualification and contingency planning.

What is the FDA Orange Book status of abaloparatide, and how does it affect supplier risk?

Orange Book linkage to manufacturing and ANDA/505(b)(2) exposure

Abaloparatide (Tymlos) has an exclusivity and patent landscape that impacts:

ANDA eligibility and potential Paragraph IV challenges
Risk that a generic or 505(b)(2) competitor induces injunction pressure or licensing disputes that disrupt supply sourcing

Supplier selection and contract structuring should include patent-aware contingencies, especially for:

Pen-device system integration
Formulation and stability-related steps
Sterile manufacturing process steps that can overlap with method and manufacturing patents

Which generics or biosimilar candidates create supplier demand risk for abaloparatide?

Abaloparatide is a small synthetic peptide-like drug administered by injection. Competitive demand risk typically comes from:

505(b)(2) or ANDA entrants targeting the same indication and dose form
Potential challengers that use different manufacturing processes or pen-device systems

For suppliers, the key commercial question is:

Whether scale-up capacity is constrained by DP sterile fill-finish slot availability during launch windows

Public challenger lists require exact FDA-related filings and Orange Book mapping to support a factual supplier risk analysis.

What formulations and device components are protected for abaloparatide injection?

Why device and formulation sourcing overlaps with patent scope

For prefilled pen injectables, supplier decisions can trigger:

Patent overlap on formulation composition
Patent overlap on manufacturing process or stability
Patent overlap on device system integration

A supplier strategy that separates device procurement from drug product fill-finish can reduce dependency, but it can also introduce new IP exposure in pen mechanism design and compatibility.

Which suppliers provide sterile fill-finish capabilities for prefilled pen systems?

Capability checklist used by buyers

Drug product CDMO qualification typically requires:

Aseptic processing certification appropriate to the product
Documented experience with prefilled pen assembly and packaging
Validation for container closure integrity, particulate matter control, and sterility assurance
Traceability and batch release testing for peptide-like compounds

This is the shortlist used to screen for credible supply without creating technical gaps during technology transfer.

How do you choose an abaloparatide supplier for licensing or litigation readiness?

Supplier contract clauses that matter for patent and regulatory posture

For abaloparatide sourcing, supplier agreements that reduce business risk typically include:

Full disclosure of manufacturing process and change control ownership
Right to audit and access of batch records for compliance and litigation defense
Assignment or licensing of improvements to process knowledge (where applicable)
Data ownership clauses covering analytical method validation and stability packages
Clear responsibility for recalls, sterility failures, and deviation investigations

These clauses are particularly relevant when supply disruptions could be tied to manufacturing process changes.

Competitive landscape: how does supplier concentration change commercial outcomes for Tymlos?

Supplier concentration affects:

Launch responsiveness for follow-on versions
Ability to absorb GMP disruptions
Cost of goods and lead times
Resilience during regulatory or quality events

For injectable pens, sterile fill-finish capacity is frequently a gating factor, so buyer concentration can reduce availability for alternative projects.

Key Takeaways

Abaloparatide’s supply chain is built around Tymlos, a prefilled pen sterile injectable, so supplier sourcing must be analyzed across API manufacture, sterile drug product fill-finish, and device/prefill system components.
Supplier selection should be performed at the facility level and tied to GMP and regulatory disclosures, not only corporate names.
Patent and exclusivity status influences supplier risk exposure by affecting competitive entry timelines and the likelihood of regulatory or litigation disruptions impacting manufacturing continuity.
For licensing and litigation readiness, contract structures must cover change control, data ownership, audit rights, and batch record accessibility.

FAQs

What is the difference between abaloparatide API suppliers and Tymlos drug product suppliers?

API suppliers manufacture the active ingredient; drug product suppliers perform sterile formulation, aseptic filling, and often prefilled pen assembly and packaging.

Do abatoparatide pen components come from the same supplier as the sterile fill-finish?

Often they are coordinated across vendors. Some CDMOs integrate device components; others source pen hardware from specialized device suppliers.

How do CMO changes affect abaloparatide regulatory compliance?

CMO and process changes require regulatory comparability assessments, validation updates, and stability/analytical method alignment to maintain product consistency.

Can a supplier sell abaloparatide to multiple brands without IP risk?

In practice, API and process supply can be constrained by patent coverage, license terms, and regulatory submissions tied to specific manufacturing processes and formulation/impurity control.

What supply chain bottleneck is most common for prefilled abaloparatide pens?

Sterile fill-finish and pen assembly capacity are typically the bottlenecks due to aseptic processing validation lead times and constrained GMP slot availability.

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
Tymlos (abaloparatide injection, USP) prescribing information. (n.d.). Radius Health, Inc. / current US marketer label.

Suppliers and packagers for generic pharmaceutical drug: ABALOPARATIDE

ABALOPARATIDE